The FDA is phasing out its animal testing requirements for monoclonal antibodies and other therapies, replacing them with “more effective, human-relevant methods,” the agency announced Thursday.
This push is not new, William Blair analysts pointed out in a Thursday note to investors. In September 2022, for instance, Congress filed the FDA Modernization Act 2.0, which proposed a broader category of studies, dubbed “nonclinical tests,” which include…
Article Source
https://www.biospace.com/fda/fda-to-replace-some-animal-testing-with-ai-human-organoid-lab-models
